Skip to main content

Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion

Inversago's drugs use a different approach than most treatments in the obesity and diabetes space.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.